Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

समान संसाधन

• Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
  द्वारा: Guy, Holly, और अन्य
  प्रकाशित: (2018)
• COST-EFFECTIVENESS OF NIRAPARIB, RUCAPARIB, AND OLAPARIB FOR TREATMENT OF PLATINUM-RESISTANT, RECURRENT OVARIAN CARCINOMA
  द्वारा: WOLFORD, JULIET E., और अन्य
  प्रकाशित: (2020)
• Rucaparib and Niraparib in Advanced Ovarian Cancer
  द्वारा: Redelico, Tyler
  प्रकाशित: (2019)
• Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
  द्वारा: Murai, Junko, और अन्य
  प्रकाशित: (2013)
• Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
  द्वारा: Oza, Amit M., और अन्य
  प्रकाशित: (2020)